Clinical outcomes of patients with breast cancer in a phase i clinic: The M. D. Anderson cancer center experience

Clinical Breast Cancer

Volumn 10, Issue 1, 2010, Pages 46-51

  Wheler, Jennifer ^a   Tsimberidou, Apostolia M ^a   Moulder, Stacy ^a   Cristofanilli, Massimo ^a   Hong, David ^a   Naing, Aung ^a   Pathak, Raminder ^a   Liu, Suyu ^a   Feng, Lei ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Absolute neutrophil count; Albumin; Outcome predictors; Performance status

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 76949107605     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.006     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Yabroff KR, Bradley CJ, Mariotto AB, et al. Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst 2008; 100:1755-1762
3. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14:1368-1376
4. Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 2008; 44:30-38
5. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182
6. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676
7. Julka PK, Chacko RT, Nag S, et al. A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer 2008; 98:1327-1335
8. Kurzrock R, Benjamin RS. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 2005; 352:930-932
9. Wheler J, Tsimberidou AM, Hong D, et al. Survival of patients in a Phase 1 clinic: the M. D. Anderson Cancer Center Experience. Cancer 2009; 115:1091-1099
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
11. Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triplenegative breast cancer. Breast Cancer Res Treat 2009; 115:423-428
12. Merajver SD, Sabel MS. Inflammatory breast cancer. In: Diseases of the Breast, 3rd Edition. Harris JR, Lippman ME, Morrow M, et al, eds. Philadelphia: Lippincott Williams and Wilkins, 2004.
13. Seidenfeld J, Horstmann E, Emmanuel EJ, et al. Participants in phase 1 oncology research trials: are they vulnerable? Arch Intern Med 2008; 168:16-20.
14. Arkenau HT, Olmos D, Ang JE, et al. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer 2008; 44:1536-1540
15. Han C, Braybrooke JP, Deplanque G, et al. Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 2003; 89:1166-1171
16. Sharma R, Hook J, Kumar M, et al. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 2008; 44:251-256
17. Janisch L, Mick R, Schilsky RL, et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 1994; 74:1965-1973
18. Coates RJ, Clark WS, Eley JW, et al. Race, nutritional status, and survival from breast cancer. J Natl Cancer Inst 1990; 82:1684-1692
19. Steinberg J, Erlichman C, Gadalla T, et al. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 1992; 28A:1817-1820
20. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007; 110:1911-1928
21. Argiles JM, Busquets S, Lopez-Soriano FJ. Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res 2006; 130:199-217.
22. Ebrahimi B, Tucker SL, Li D, et al. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004; 101:2727-2736
23. Chlebowski RT, Palomares MR, Lillington L, et al. Recent implications of weight loss in lung cancer management. Nutrition 1996; 12(1 suppl):S43-7.
24. Paesmans M, Sculier JP, Libert P, et al. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer 1997; 33:2326-2332
25. Alexandre J, Gross-Goupil M, Falissard B, et al. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 2003; 14:36-41.
26. Charles KA, Rivory LP, Stockler MR, et al. Predicting the toxicity of weekly docetaxel in advanced cancer. Clin Pharmacokinet 2006; 45:611-622
27. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005; 352:895-904.
28. Roberts TG Jr, Goulart BH, Sqitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004; 292:2130-2140